Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?

Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?

Background and Aims: Irritable bowel syndrome (IBS) is a chronic relapsing disorder characterized by abdominal pain-discomfort and altered bowel habits. The IBS-diarrhoea predominant subtype (IBS-D) is defined as >25% of bowel movements representing type 6 or 7 of the Bristol Stool Form Scale. Ma...

Full description

Bibliographic Details
Main Authors: Dwaipayan Sarathi Chakraborty, Avijit Hazra, Amrita Sil, Shantasil Pain
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Journal of Family Medicine and Primary Care
Subjects:
diarrhoea
irritable bowel syndrome
mebeverine
randomized controlled trial
Online Access:http://www.jfmpc.com/article.asp?issn=2249-4863;year=2019;volume=8;issue=10;spage=3173;epage=3178;aulast=Chakraborty

Internet

http://www.jfmpc.com/article.asp?issn=2249-4863;year=2019;volume=8;issue=10;spage=3173;epage=3178;aulast=Chakraborty

Similar Items